Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Angela, Grove"'
Autor:
Jon Shaffer, Angela Grove
Publikováno v:
Platelets, Vol 33, Iss 5, Pp 790-791 (2022)
There is limited data on the use of caplacizumab beyond the initial treatment course. We describe a patient case demonstrating the efficacy of a second course of caplacizumab in a patient with relapsed acquired thrombotic thrombocytopenic purpura (TT
Externí odkaz:
https://doaj.org/article/9dc22b9592f941fda4acd75d88e35b1d
Autor:
Mengni, Guo, Jieying, Liu, Ruoyu, Miao, Zohaib, Ahmed, James, Yu, Jian, Guan, Sarfraz, Ahmad, Shuntai, Zhou, Angela, Grove, Manoucher, Manoucheri, Mark A, Socinski, Tarek, Mekhail
Publikováno v:
Journal of Immunotherapy. 45:389-395
Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events (irAEs). The coronavirus disease 2019 (COVID-19) is associated with increased amounts of pro-inflammatory cytokines, which may affect the outcome of irAEs. Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::318b3f890b4356a526eb41306722fe39
https://doi.org/10.1097/cji.0000000000000440
https://doi.org/10.1097/cji.0000000000000440
Autor:
Jon Shaffer, Angela Grove
Publikováno v:
Platelets. 33(5)
There is limited data on the use of caplacizumab beyond the initial treatment course. We describe a patient case demonstrating the efficacy of a second course of caplacizumab in a patient with relapsed acquired thrombotic thrombocytopenic purpura (TT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98c9d89c0446b691aae9b4366abf4312
https://pubmed.ncbi.nlm.nih.gov/34565299
https://pubmed.ncbi.nlm.nih.gov/34565299
Autor:
Mengni Guo, Jieying Liu, Zohaib Ahmed, James Yu, Ruoyu Miao, Jian Guan, Mohammad Ali Esmaeil Pour, Azadeh Khayyat, Angela Grove, Manoucher Manoucheri, Mark A. Socinski, Tarek Mekhail
Publikováno v:
Journal of Clinical Oncology. 40:2525-2525
2525 Background: Immune checkpoint inhibitors (ICIs) can cause a variety of inflammatory autoimmune tissue damage, referred to as immune-related adverse events (irAEs). COVID-19 is associated with increased amounts of proinflammatory cytokines, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0800d27e8b6156a1b660a365eb71a6c1
https://doi.org/10.1200/jco.2022.40.16_suppl.2525
https://doi.org/10.1200/jco.2022.40.16_suppl.2525